Johnson & Johnson said adjusted earnings for the three months ending in December came in at $1.88 per share, down 4.6% from last year but one penny ahead of the Street consensus forecast … to …

More Johnson & Johnson Tops Q4 Earnings Forecast, But Light Revenues, Remicade Sales Hit Shares Videos